Literature DB >> 20299101

Hybrid IgG4/IgG4 Fc antibodies form upon 'Fab-arm' exchange as demonstrated by SDS-PAGE or size-exclusion chromatography.

Theo Rispens1, Tamara H den Bleker, Rob C Aalberse.   

Abstract

Human IgG4 antibodies are dynamic molecules that in vivo exchange half-molecules to become bispecific antibodies. Here we show that IgG4 antibodies and IgG4 Fc fragments similarly exchange resulting in hybrid antibodies (a single Fab+Fc) with a molecular weight of ca. 100kDa. These antibodies can be separated from IgG4 and IgG4 Fc using size-exclusion chromatography and non-reducing SDS-PAGE. This method does not rely on a cross-linking immunoassay with its potential for false-positive results due to aggregation and it unambiguously demonstrates that the 'Fab-arm' exchange process depends entirely on the Fc part (hinge+CH2+CH3). Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299101     DOI: 10.1016/j.molimm.2010.02.021

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

1.  The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.

Authors:  John-Paul Silva; Olivia Vetterlein; Joby Jose; Shirley Peters; Hishani Kirby
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

2.  Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.

Authors:  Ian C Wilkinson; Susan B Fowler; Leeann Machiesky; Kenneth Miller; David B Hayes; Morshed Adib; Cheng Her; M Jack Borrok; Ping Tsui; Matthew Burrell; Dominic J Corkill; Susanne Witt; David C Lowe; Carl I Webster
Journal:  MAbs       Date:  2013-04-08       Impact factor: 5.857

3.  Estimation of polyclonal IgG4 hybrids in normal human serum.

Authors:  Elizabeth Young; Emma Lock; Douglas G Ward; Alexander Cook; Stephen Harding; Gregg L F Wallis
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 4.  Opening the door to innovation.

Authors:  Janine Schuurman; Yvo F Graus; Aran F Labrijn; Sigrid Ruuls; Paul W H I Parren
Journal:  MAbs       Date:  2014-04-24       Impact factor: 5.857

5.  Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class.

Authors:  T S Dodev; H Bowen; M H Shamji; H J Bax; A J Beavil; J M McDonnell; S R Durham; B J Sutton; H J Gould; L K James
Journal:  Allergy       Date:  2015-03-28       Impact factor: 13.146

Review 6.  Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions.

Authors:  Louisa K James; Stephen J Till
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

7.  Human milk IgGs contain various combinations of different antigen-binding sites resulting in multiple variants of their bispecificity.

Authors:  Sergey E Sedykh; Valentina N Buneva; Georgy A Nevinsky
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

8.  Human milk sIgA molecules contain various combinations of different antigen-binding sites resulting in a multiple binding specificity of antibodies and enzymatic activities of abzymes.

Authors:  Sergey E Sedykh; Valentina N Buneva; Georgy A Nevinsky
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

9.  The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity.

Authors:  Lucy E Rayner; Gar Kay Hui; Jayesh Gor; Richard K Heenan; Paul A Dalby; Stephen J Perkins
Journal:  J Biol Chem       Date:  2014-05-29       Impact factor: 5.157

10.  Increased Kappa/Lambda Hybrid Antibody in Serum Is a Novel Biomarker Related to Disease Activity and Inflammation in Rheumatoid Arthritis.

Authors:  Lang Yi; Mingju Hao; Tian Lu; Guigao Lin; Lida Chen; Ming Gao; Gaowei Fan; Dong Zhang; Guojing Wang; Xin Yang; Yulong Li; Kuo Zhang; Rui Zhang; Yanxi Han; Lunan Wang; Jinming Li
Journal:  Mediators Inflamm       Date:  2016-04-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.